Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,386

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678

The Novel Coronavirus Originating in Wuhan, China

Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Whitt, M. A. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.08.006 · Cited by 431

The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain

Wu, J., Nie, J., Zhang, L., Song, H., An, Y., Liang, Z., Yang, J., Ding, R., Liu, S., Li, Q., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00874-7 · Cited by 18

Recent Progresses in Electrochemical DNA Biosensors for SARS-CoV-2 Detection

Mei, Y., Lin, X., He, C., Zeng, W., Luo, Y., Liu, C., Liu, Z., Yang, M., Kuang, Y., & Huang, Q. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.952510 · Cited by 18

SARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin deposition

Erickson, R. I., Huang, C., Allen, C., Ireland, J., Roth, G., Zou, Z., Lu, J., Lafont, B. A. P., Garza, N. L., Brumbaugh, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42140-6 · Cited by 19

Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications

Jiang, J.-C., & Zhang, Y. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200744 · Cited by 19

Development of receptor binding domain-based double-antigen sandwich lateral flow immunoassay for the detection and evaluation of SARS-CoV-2 neutralizing antibody in clinical sera samples compared with the conventional virus neutralization test

Zhang, Y., Chen, Y., He, Y., Li, Y., Zhang, X., Liang, J., He, J., Lü, S., Gao, Z., Xu, J., et al. (2022) · Talanta · doi:10.1016/j.talanta.2022.124200 · Cited by 18

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants

Wang, X., Lin, Y., Zhang, H.-Y., Zhu, K.-L., Zhao, J., Zhan, B., Li, Y., He, X.-J., Huang, C., Wang, Z.-Y., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01151-6 · Cited by 18

Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus

Gracheva, A. V., Korchevaya, E. R., Kudryashova, A. M., Borisova, O. V., Petrusha, О. А., Smirnova, D. I., Chernyshova, I. N., Свитич, О. А., Зверев, В. В., & Файзулоев, Е. Б. (2021) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-136 · Cited by 17

Computational study of 2D photonic crystal based biosensor for SARS-COV-2 detection

Miyan, H., Agrahari, R., Gowre, S. C., Jain, P. K., & Mahto, M. (2023) · Measurement Science and Technology · doi:10.1088/1361-6501/acc754 · Cited by 17

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

Liu, C., Das, R., Dijokaite-Guraliuc, A., Zhou, D., Mentzer, A. J., Supasa, P., Selvaraj, M., Duyvesteyn, H. M. E., Ritter, T. G., Temperton, N. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47393-3 · Cited by 17

From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2

Kumar, A., Tripathi, P., Kumar, P., Shekhar, R., & Pathak, R. (2024) · Vaccines · doi:10.3390/vaccines12050459 · Cited by 17

Improving antibody affinity through in vitro mutagenesis in complementarity determining regions

Ye, W., Liu, X., He, R., Gou, L., Lü, M., Yang, G., Wen, J., Wang, X., Liu, F., Ma, S., et al. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20220003 · Cited by 17

Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses

Li, Q., Zhang, L., Liang, Z., Wang, N., Liu, S., Li, T., Yu, Y., Cui, Q., Wu, X., Nie, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01123-7 · Cited by 17

Pseudotyped Viruses

Wang, Y., Zhou, Z., Wu, X., Li, T., Wu, J., Cai, M., Nie, J., Wang, W., & Cui, Z. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-0113-5_1 · Cited by 17

Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2

Zhao, M., Su, P.-Y., Castro, D. A., Tripler, T. N., Hu, Y., Cook, M., Ko, A. I., Farhadian, S., Israelow, B., Cruz, C. S. D., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009683 · Cited by 17

Rapid electrochemical immunodetection of SARS-CoV-2 using a pseudo-typed vesicular stomatitis virus model

Ashur, I., Alter, J., Werbner, M., Ogungbile, A., Dessau, M. A., Gal-Tanamy, M., & Vernick, S. (2021) · Talanta · doi:10.1016/j.talanta.2021.123147 · Cited by 16

High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020

Zhang, S., Ma, P., Orzechowski, M., Lemmer, A., Rzasa, K. M., Bagnall, J., Barkho, S., Chen, M., He, L. L., Neitupski, R., et al. (2023) · mBio · doi:10.1128/mbio.03523-22 · Cited by 16

A pangolin-origin SARS-CoV-2-related coronavirus: infectivity, pathogenicity, and cross-protection by preexisting immunity

Huang, X., Chen, Q., Sun, M., Zhou, H., Ye, Q., Chen, W., Peng, J.-Y., Qi, Y., Zhai, J., Tian, Y., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00557-9 · Cited by 16

The next‐generation coronavirus diagnostic techniques with particular emphasis on the SARS‐CoV‐2

Hemida, M. G. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26926 · Cited by 16

Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology

Codd, A. S., Hanna, S. J., Compeer, E. B., Richter, F. C., Pring, E. J., Gea-Mallorquí, E., Borsa, M., Moon, O. R., Scourfield, D. O., Ahern, D., et al. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab016 · Cited by 16

Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs

Hetrick, B., Chilin, L. D., He, S., Dabbagh, D., Alem, F., Narayanan, A., Luchini, A., Li, T., Liu, X., Copeland, J., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100181 · Cited by 17

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV

Wang, Q., Song, Z., Yang, J., He, Q., Mao, Q., Bai, Y., Liu, J., An, C., Yan, X., Cui, B., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2059404 · Cited by 16

Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2

Li, C., Zhou, H., Guo, L., Xie, D., He, H., Zhang, H., Liu, Y., Peng, L., Zheng, L., Lu, W., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03501-9 · Cited by 16

Return to work for healthcare workers with confirmed COVID-19 infection

Zhang, J. C., Findlater, A. R., Cram, P. M., & Adisesh, A. (2020) · Occupational Medicine · doi:10.1093/occmed/kqaa092 · Cited by 16

Rapid Quantification and Neutralization Assays for Novel Coronavirus SARS-CoV-2 Using Avicel RC-591 Semi-Solid OverlayPreprint

Honko, A. N., Storm, N., Bean, D. J., Vasquez, J. H., Downs, S. N., & Griffiths, A. (2020) · Preprints.org · doi:10.20944/preprints202005.0264.v1 · Cited by 16

Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain

Niu, X., Li, Z., Wang, J., Jian, F., Yu, Y., Song, W., Yisimayi, A., Du, S., Zhang, Z., Wang, Q., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2412990 · Cited by 15

Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist

Wang, X., Zhang, M., He, N., Wang, Y., Yan, C., Chen, X., Gao, X.-F., Guo, J., Luo, R., & Liu, Z. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00881 · Cited by 15

Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy

Cheng, Z. J., Li, B., Zhan, Z., Zhao, Z., Xue, M., Zheng, P., Lyu, J., Hu, C., He, J., Chen, R., et al. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08912-y · Cited by 15

Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera

Streif, S., Neckermann, P., Spitzenberg, C., Weiß, K. T., Hoecherl, K., Kulikowski, K., Hahner, S., Nölting, C., Einhauser, S., Peterhoff, D., et al. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04548-3 · Cited by 17

Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2

Song, D., Wang, W., Dong, C., Ning, Z., Liu, X., Liu, C., Du, G., Sha, C., Wang, K., Lu, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02029-w · Cited by 15

Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants

Nie, J., Xie, J., Liu, S., Wu, J., Liu, C., Li, J., Liu, Y., Wang, M., Zhao, H., Zhang, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00292-z · Cited by 15

Synthesis and Biological Evaluation of Honokiol Derivatives Bearing 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones as Potential Viral Entry Inhibitors against SARS-CoV-2

Guo, Y., Meng, J., Liu, J., Xu, T., Zheng, Z., Jiang, Z., & Bai, L. (2021) · Pharmaceuticals · doi:10.3390/ph14090885 · Cited by 15

LRR-protein RNH1 dampens the inflammasome activation and is associated with COVID-19 severity

Bombaci, G., Sarangdhar, M. A., Andina, N. D., Tardivel, A., Yu, E. C.-W., Mackie, G. M., Pugh, M., Ozan, V. B., Banz, Y., Spinetti, T., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101226 · Cited by 15

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines

Liu, J., Mao, Q., Wu, X., He, Q., Bian, L., Bai, Y., Wang, Z., Wang, Q., Zhang, J., Liang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.814365 · Cited by 15

A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer response

Devi, M. J., Gaffar, S., & Hartati, Y. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2022.114902 · Cited by 12

Identification of Drugs Blocking SARS-CoV-2 Infection using Human Pluripotent Stem Cell-derived Colonic OrganoidsPreprint

Duan, X., Han, Y., Yang, L., Nilsson-Payant, B. E., Wang, P., Zhang, T., Xiang, J., Xu, D., Wang, X., Uhl, S. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.02.073320 · Cited by 15

Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2Preprint

Vandergaast, R., Carey, T. S., Reiter, S., Lech, P. J., Gnanadurai, C. W., Tesfay, M. Z., Buehler, J., Suksanpaisan, L., Naik, S., Brunton, B. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.26.117549 · Cited by 15

Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidatePreprint

Su, D., Li, X., He, C., Huang, X., Chen, M., Wang, Q., Qin, W., Liang, Y. S., Xu, R., Wu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.16.444369 · Cited by 15

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity

Tang, H., Gao, L., Wu, Z., Meng, F., Zhao, X., Shao, Y., Shi, X., Qiao, S., An, J., Du, X., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.720357 · Cited by 15

Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China

Zhang, H., Hua, Q., Xu, N., Zhang, X., Chen, B., Xi-jun, M., Hu, J., Chen, Z., Yu, P., Lei, H., et al. (2023) · eLife · doi:10.7554/elife.84056 · Cited by 17

The development and application of pseudoviruses: assessment of SARS-CoV-2 pseudoviruses

Tan, C., Wang, N., Deng, S., Wu, X., Yue, C., Jia, X., & Lyu, Y. (2023) · PeerJ · doi:10.7717/peerj.16234 · Cited by 14

Natural products as a source of Coronavirus entry inhibitors

Szabó, D., Crowe, A. P., Mamotte, C. D. S., & Strappe, P. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1353971 · Cited by 14

A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

Cai, Z., Kalkeri, R., Zhu, M., Cloney-Clark, S., Haner, B., Wang, M., Osman, B., Dent, D., Feng, S.-L. Y., Longacre, Z., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12030501 · Cited by 14

Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1

Yang, S., Yu, Y., Jian, F., Yisimayi, A., Song, W., Liu, J., Wang, P., Xu, Y., Wang, J., Niu, X., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2343909 · Cited by 15

A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug

Liu, Q., Cai, C., 黄燕燕, Zhou, L., Guan, Y., Fu, S., Lin, Y., Yang, T., Yan, H., Zhang, Z., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06802-7 · Cited by 14

SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020

Lumley, S., Eyre, D. W., McNaughton, A. L., Howarth, A., Hoosdally, S., Hatch, S. B., Kavanagh, J., Chau, K., Downs, L., Cox, S., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.41.2001721 · Cited by 14

The theory and practice of the viral dose in neutralization assay: Insights on SARS-CoV-2 “doublethink” effect

Manenti, A., Molesti, E., Maggetti, M., Torelli, A., Lapini, G., & Montomoli, E. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114261 · Cited by 14

Resilient Built Environment: Critical Review of the Strategies Released by the Sustainability Rating Systems in Response to the COVID-19 Pandemic

Marotta, A., Porras-Amores, C., & Sánchez, A. R. (2021) · Sustainability · doi:10.3390/su132011164 · Cited by 14

Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism

Zhang, X., Shi, Y., Guo, Z., Zhao, X., Wu, J., Cao, S., Liu, Y., Li, Y., Huang, W., Wang, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114209 · Cited by 14

Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer

Connelly, G. G., Kirkland, O. O., Bohannon, S., Lim, D., Wilson, R. M., Richards, E. J., Tay, D. M. Y., Jee, H., Hellinger, R. D., Hoang, N. K., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100273 · Cited by 16

A Neutralization Assay Based on Pseudo-Typed Lentivirus with SARS CoV-2 Spike Protein in ACE2-Expressing CRFK Cells

Pısıl, Y., Shida, H., & Miura, T. (2021) · Pathogens · doi:10.3390/pathogens10020153 · Cited by 15

Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2

Sun, X., Yang, S., Al‐Dossary, A. A., Broitman, S., Ni, Y., Guan, M., Yang, M., & Li, J. (2022) · Applied and Environmental Microbiology · doi:10.1128/aem.02303-21 · Cited by 14

A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies

Prashar, P., Swain, S., Adhikari, N., Aryan, P., Singh, A., Kwatra, M., & Prabhakar, B. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105349 · Cited by 16

Gene expression pattern differences in primary human pulmonary epithelial cells infected with MERS-CoV or SARS-CoV-2

Jang, Y., & Seo, S. H. (2020) · Archives of Virology · doi:10.1007/s00705-020-04730-3 · Cited by 13

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants

Qu, Y., Zhang, X., Wang, M., Sun, L., Jiang, Y., Li, C., Wu, W., Chen, Z., Yin, Q., Jiang, X., et al. (2021) · Virologica Sinica · doi:10.1007/s12250-021-00409-4 · Cited by 14

Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Chong, Z. X., Liew, W.-P.-P., Ong, H. K., Yong, C. Y., Shit, C. S., Ho, W. Y., Ng, S., & Yeap, S. K. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153565 · Cited by 13

Syndecan-4 Is a Key Facilitator of the SARS-CoV-2 Delta Variant’s Superior Transmission

Hudák, A., Veres, G., Letoha, A., Szilák, L., & Letoha, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020796 · Cited by 13

Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng

Moon, J., Jung, Y., Moon, S., Hwang, J., Kim, S., Kim, M. S., Yoon, J. H., Kim, K., Park, Y., Cho, J. Y., et al. (2022) · Journal of Ginseng Research · doi:10.1016/j.jgr.2022.07.003 · Cited by 13

Development of Fluorescence-Tagged SARS-CoV-2 Virus-like Particles by a Tri-Cistronic Vector Expression System for Investigating the Cellular Entry of SARS-CoV-2

Chang, Y.-S., Chu, L.-W., Chen, Z.-Y., Wu, J.-S., Su, W., Yang, C., Ping, Y., & Lin, C. (2022) · Viruses · doi:10.3390/v14122825 · Cited by 13

Gold nanoparticle-based immunochromatographic assay for the rapid detection of the SARS-CoV-2 Omicron variant

Ye, L., Lei, X., Xu, L., Kuang, H., Xu, C., & Xu, X. (2023) · Materials Chemistry Frontiers · doi:10.1039/d3qm00624g · Cited by 13

An Overview of the Conventional and Novel Methods Employed for SARS-CoV-2 Neutralizing Antibody Measurement

Rocha, V. P. C., Quadros, H. C., Fernandes, A. M. S., Gonçalves, L. P., Badaró, R. J. D. S., Soares, M. B. P., & Machado, B. A. S. (2023) · Viruses · doi:10.3390/v15071504 · Cited by 13

The first Chinese national standards for SARS-CoV-2 neutralizing antibody

Guan, L., Yu, Y., Wu, X., Nie, J., Zhang, J., Wang, Z., Li, N., Shi, R., Zhao, H. J., Chen, H., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.047 · Cited by 13

SARS-CoV-2 might transmit through the skin while the skin barrier function could be the mediator

Xu, Q., Zhang, L., Chen, L., Zhao, X., Wang, X., Hu, M., Le, Y., Xue, F., Li, X., & Zheng, J. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110752 · Cited by 12

Smoke and Spike: Benzo[a]pyrene Enhances SARS‐CoV‐2 Infection by Boosting NR4A2‐Induced ACE2 and TMPRSS2 Expression

Liu, W., Zhao, Y., Fan, J., Shen, J., Tang, H., Tang, W., Wu, D., Huang, W., Ding, Y., Peng, Q., et al. (2023) · Advanced Science · doi:10.1002/advs.202300834 · Cited by 12

Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection

Jiang, X., Song, X., Shi, C., Yang, G., Wang, X., Zhang, Y.-W., Wu, J., Zhao, L., Zhang, M., Wang, M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114387 · Cited by 13

Lessons learned in the collection of convalescent plasma during the COVID‐19 pandemic

Wendel, S., Land, K. J., Devine, D. V., Daly, J. J., Bazin, R., Tiberghien, P., Lee, C. K., Arora, S., Patidar, G. K., Khillan, K., et al. (2021) · Vox Sanguinis · doi:10.1111/vox.13096 · Cited by 12

Maintenance of neutralizing antibodies over ten months in convalescent SARS‐CoV‐2 afflicted patients

Sonnleitner, S. T., Prelog, M., Jansen, B., Rodgarkia‐Dara, C., Gietl, S., Schönegger, C. M., Koblmüller, S., Sturmbauer, C., Posch, W., Almanzar, G., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14130 · Cited by 12

Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage

Wang, K., Wu, J., XinZHANG, Zeng, Q., Zhang, N., Huang, W., Tang, S., Wang, Y., Kong, W., Wang, Y., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105196 · Cited by 12

Development of an Adeno-Associated Virus-Vectored SARS-CoV-2 Vaccine and Its Immunogenicity in Mice

Qin, X., Li, S., Li, X., Pei, D., Liu, Y., Ding, Y., Liu, L., Bi, H., Shi, X., Guo, Y., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.802147 · Cited by 12

Well-differentiated liver cancers reveal the potential link between ACE2 dysfunction and metabolic breakdown

Desquilles, L., Cano, L., Ghukasyan, G., Mouchet, N., Landreau, C., Corlu, A., Clément, B., Turlin, B., Désert, R., & Musso, O. C. (2022) · Scientific Reports · doi:10.1038/s41598-021-03710-0 · Cited by 12

A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory

Zou, J., Xia, H., Shi, P., Xie, X., & Ren, P. (2022) · Viruses · doi:10.3390/v14061211 · Cited by 12

Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations

Helmy, S. A., Morsi, R. M. E., El-Masry, S. M., & El-Masry, S. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103762 · Cited by 12

Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test

Merluza, J., Ung, J., Makowski, K., Robinson, A., Manguiat, K., Mueller, N., Audet, J., Chen, J. C.-Y., Strong, J. E., Wood, H., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03789-22 · Cited by 12

SARS-CoV-2 infection of intestinal epithelia cells sensed by RIG-I and DHX-15 evokes innate immune response and immune cross-talk

Zhang, L., Zhang, Y., Wang, R., Liu, X., Zhao, J., Tsuda, M., & Li, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1035711 · Cited by 12

Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization

Zhu, Y., Sarıbaş, A. S., Liu, J., Lin, Y., Bodnar, B. H., Zhao, R., Guo, Q., Ting, J., Wei, Z., Ellis, A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.012 · Cited by 12

CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation

Xiao, Y., Yan, Y., Chang, L., Ji, H., Sun, H., Song, S., Feng, K., Nuermaimaiti, A., Lu, Z., & Wang, L. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105558 · Cited by 12

Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5‐ and BA.5‐XBB‐convalescent subpopulations

Yang, X., Wang, Y., Liang, Z., Cui, T., Chen, D., Li, G., Xu, H. Y., Liu, S., Zhong, N., Huang, W., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29417 · Cited by 12

Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients

McEvoy, C. M., Hu, Q., Abe, K. T., Yau, K., Oliver, M. J., Levin, A., Gingras, A., Hladunewich, M., & Yuen, D. A. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001401 · Cited by 12

Impedance-Based Neutralizing Antibody Detection Biosensor with Application in SARS-CoV-2 Infection

Manshadi, M. K. D., Mansoorifar, A., Chiao, J. ‐., & Beşkök, A. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03193 · Cited by 11

Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays

Manu, A. A., Owusu, I. A., Oyawoye, F. O., Languon, S., Ibrahim, B. A., Tawiah-Eshun, S., Quaye, O., Donkor, J. K., Paemka, L., Amegatcher, G., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31392 · Cited by 11

A High-Throughput Broad Neutralizing Antibody Assay for Detecting SARS-CoV-2 Variant Immunity in Population

Zhang, X., Wang, Y., Li, M., Li, H., Zhang, X., Xu, X., Ma, Q., Hu, D., Jia, Y., Liang, T., et al. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00402 · Cited by 11

Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics

Neumaier, F., Zlatopolskiy, B. D., & Neumaier, B. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121247 · Cited by 12

Adaptive immune responses to SARS-CoV-2

Forthal, D. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.009 · Cited by 11

Fc-Mediated E2-Dimer Subunit Vaccines of Atypical Porcine Pestivirus Induce Efficient Humoral and Cellular Immune Responses in Piglets

Ren, X., Qian, P., Liu, S., Chen, H., & Li, X. (2021) · Viruses · doi:10.3390/v13122443 · Cited by 11

Dynamic observation of SARS‐CoV‐2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVID‐19 vaccination

Jiang, R., Dou, X., Li, M., Wang, E., Hu, J., Xiong, D., & Zhang, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24325 · Cited by 11

A Novel and Secure Pseudovirus Reporter System Based Assay for Neutralizing and Enhancing Antibody Assay Against Marburg Virus

Bi, J., Wang, H., Pei, H., Han, Q., Feng, N., Wang, Q., Wang, X., Wang, Z., Wei, S., Ge, L., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.927122 · Cited by 11

An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV

Zhang, H., Jin, H., Yan, F., Song, Y., Dai, J., Jiao, C., Bai, Y., Sun, J., Liu, D., Wang, S., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.12.006 · Cited by 11

Development of an Effective Neutralizing Antibody Assay for SARS-CoV-2 Diagnosis

Liu, Z., Liang, J., Hu, H., Wu, M., Ma, J., Ma, Z., Ji, J., Chen, H., Li, X., Wang, Z., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s408921 · Cited by 11

Development of a Bioluminescent Imaging Mouse Model for SARS-CoV-2 Infection Based on a Pseudovirus System

Wu, X., Fang, N., Liang, Z., Nie, J., Lang, S., Fan, C., Liang, C., Huang, W., & Wang, Y. (2023) · Vaccines · doi:10.3390/vaccines11071133 · Cited by 11

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector

Liang, Z., Wu, X., Wu, J., Liu, S., Tong, J., Li, T., Yu, Y., Zhang, L., Zhao, C., Lu, Q., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2261566 · Cited by 11

Binding affinity between coronavirus spike protein and human ACE2 receptor

Shum, M. H.-H., Lee, Y., Tam, L., Xia, H., Chung, L. W., Guo, Z., & Lam, T. T. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.01.009 · Cited by 12

Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma

Yu, D., Li, Y., Hong, L., Wu, J., Hu, Y., Peng, Y., Li, T., Hou, J., Huang, W., Guan, L., et al. (2022) · Advanced Science · doi:10.1002/advs.202104333 · Cited by 11

Photonic Crystal Based Ultrafast and Highly Sensitive Refractive Index Sensor

Miyan, H., Agrahari, R., Gowre, S. C., Jain, P. K., & Mahto, M. (2023) · IEEE Sensors Journal · doi:10.1109/jsen.2023.3283506 · Cited by 10

Establishment of Replication Deficient Vesicular Stomatitis Virus for Studies of PEDV Spike-Mediated Cell Entry and Its Inhibition

Luo, H., Lv, L., Yi, J., Zhou, Y., & Liu, C. (2023) · Microorganisms · doi:10.3390/microorganisms11082075 · Cited by 10

Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids

Li, K., Hu, X., Tu, X.-Y., Xian, M.-Y., Huang, L., Huang, T. H., Luo, R., Jin, H., & Liu, Z. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01801 · Cited by 10

Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in China

Huang, Z., Fu, Z., & Wang, J. (2022) · Engineering · doi:10.1016/j.eng.2022.01.001 · Cited by 10

Lactoferrin Can Attenuate SARS-CoV-2: An Analysis of Evidential Relations

Shafqat, F., Rehman, S. U., & Niaz, K. (2022) · Biomedical Research and Therapy · doi:10.15419/bmrat.v9i2.727 · Cited by 10

Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout

Lichtenegger, S., Saiger, S., Hardt, M., Kulnik, S., Wagner, G. E., Kleinhappl, B., Assig, K., Zauner, A., Ober, M., Kimpel, J., et al. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00376-22 · Cited by 11

Review on In Silico Methods, High-throughput Screening Techniques, and Cell Culture Based In Vitro Assays for SARS-CoV-2

Çetin, Y., Aydınlık, Ş., Güngör, A., Kan, T., Avşar, T., & Durdağı, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220627121416 · Cited by 11

Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro

Nyagwange, J., Kutima, B., Mwai, K., Karanja, H., Gitonga, J. N., Mugo, D., Sein, Y., Wright, D., Omuoyo, D. O., Nyiro, J. U., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.11.041 · Cited by 10

A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly

Hu, L., Tang, Y., Mei, L., Liang, M., Huang, J., Wang, X., Wu, L., Jiang, J., Li, L., Long, F., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105509 · Cited by 10

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 427

Detection of Neutralizing Antibodies in Serum Samples Using a SARS‐CoV‐2 Pseudotyped Virus Assay

Ferrero, S., Batto, M. V., Gatto, M. I., Dimase, F., & Helguera, G. F. (2024) · Current Protocols · doi:10.1002/cpz1.70025

Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay

Tolah, A. M., Sohrab, S. S., Tolah, K. M., Hassan, A. M., El-Kafrawy, S. A., & Azhar, E. I. (2021) · Diagnostics · doi:10.3390/diagnostics11060994 · Cited by 34

Design and Development of a Pseudotyped-lentivirus for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hassannia, H., Enderami, S. E., Mansour, R. N., Eftekhary, M., Abazari, M., & Salarinia, R. (2023) · DOAJ (DOAJ: Directory of Open Access Journals)

Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2

Balinsky, C. A., Jani, V., Sun, P., Williams, M., Defang, G. N., & Porter, K. R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2111-0_21 · Cited by 5